Objective:

To characterize the role of Stem Cell Factor (SCF) and its isoform SCF248 in the regulation of innate lymphoid cells type 2 (ILC2), which are critical mediators of type 2 airway inflammation, during allergic airway inflammation.

Approach:

• Transcriptional Profiling: Transcriptional profiling of SCF-deficient ILC2s was performed to assess gene expression changes related to cytokine signaling and activation.
• In Vitro Studies: In vitro experiments were conducted to observe the induction of SCF248 expression in mesenchymal cells by pro-inflammatory cytokines.
• In Vivo Validation: In vivo studies utilized tamoxifen-inducible SCF-deficient mice in an Alternaria alternata model to evaluate the effects of SCF deficiency on allergic inflammation.

Key Findings:

• SCF248 expression is upregulated in the lungs and bone marrow during allergic inflammation.
• SCF deficiency leads to reduced expression of key genes in ILC2s, impairing their inflammatory responsiveness.
• Blocking SCF248 reduces allergic inflammation and alters ILC populations in the bone marrow.

Interpretation:

SCF248 is identified as a regulator of ILC2 maturation and activation, contributing to type 2 inflammation in allergic airway disease.

Limitations:

• The study primarily focuses on mouse models, which may not fully replicate human allergic asthma.
• Further research is needed to explore the therapeutic potential of targeting SCF248 in clinical settings.

Conclusion:

SCF248 is implicated in enhancing ILC2 activation and promoting mucosal type 2 inflammation during allergic responses.